Celiac disease (CD) is a common digestive disease in persons of European descent. It is also known as celiac sprue, gluten-sensitive enteropathy, or nontropical sprue. In individuals with CD, gluten (a protein in wheat, barley, and rye) damages the small intestine and results in difficulty absorbing nutrients from food. Up to 1 in 113 people in the United States have CD. The risk is higher (1 in 22) in people with a first-degree relative with CD. The cause of CD is unknown, but environmental, immunologic, and genetic factors all contribute. The September 16, 2009, issue of JAMA includes an article about CD.
It is believed that there is an immunologic (having to do with the immune system) aspect to CD. Several autoantibodies (antibodies are normal parts of the body that fight against something trying to invade it; autoantibodies are abnormally directed against one's own body) are found in the blood in patients with CD. It is not certain whether these autoantibodies are a cause of CD or a result of damage from it. There is also a genetic component to CD. Almost all patients have a particular gene, but only a small number of people with that gene have CD. When people with CD eat foods or use products containing gluten, the immune system responds by damaging or destroying villi (tiny fingerlike protrusions lining the small intestine). Nutrients from food are absorbed through the small intestine walls into the bloodstream. Villi increase the amount of surface space in the small intestine for absorption of nutrients. Without healthy villi, people become malnourished no matter what they eat.
Grahic Jump Location
Symptoms of CD include abdominal bloating or pain; chronic diarrhea; vomiting; constipation; pale, foul-smelling, or fatty stools; and weight loss. Adults may not have as many of these symptoms as children. Rather, adults with CD are more likely to have unexplained anemia (low red blood count), fatigue, bone or joint pain, arthritis, bone loss or osteoporosis, depression or anxiety, tingling numbness in the hands and feet, or an itchy rash known as dermatitis herpetiformis.
Small-intestinal biopsy showing abnormal villi is considered the best way to diagnose CD. Many cases of CD are never diagnosed.
The only treatment for patients with CD is avoiding foods containing or made from wheat, barley, and rye for the rest of their lives. Eating even a small amount of gluten can damage the small intestine. In children, the small intestine usually heals within 3 to 6 months, but it may take years to heal in adults. Oats are safe in small amounts, although oats are often processed in facilities that also process other grains. Rice, potato, soy, and buckwheat are safe to eat. It is important for people with CD to read product labels, as gluten is used as an additive in some medications, lipstick, vitamins, and even Play-Doh.
National Institutes of Healthhttp://www.digestive.niddk.nih.gov/ddiseases/pubs/celiac/http://www.nlm.nih.gov/medlineplus/celiacdisease.html
American Dietetic Associationhttp://www.eatright.org
To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's Web site at http://www.jama.com. Many are available in English and Spanish.
Sources: National Institutes of Health, American Dietetic Association
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.
TOPIC: DIGESTIVE DISORDERS
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.